Cargando…

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions

Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariani, Luciano, Sandri, Maria Teresa, Preti, Mario, Origoni, Massimo, Costa, Silvano, Cristoforoni, Paolo, Bottari, Fabio, Sideri, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679387/ https://www.ncbi.nlm.nih.gov/pubmed/26722366 http://dx.doi.org/10.7150/jca.13503

Ejemplares similares

Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma
por: Costa, Silvano, et al.
Publicado: (2015)

E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective
por: Origoni, Massimo, et al.
Publicado: (2015)

HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
por: Bottari, Fabio, et al.
Publicado: (2022)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice
por: Origoni, M, et al.
Publicado: (2012)

VIN usual type—from the past to the future
por: Preti, Mario, et al.
Publicado: (2015)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

Evaluating HPV‐negative CIN2+ in the ATHENA trial
por: Petry, Karl Ulrich, et al.
Publicado: (2016)

Progression of CIN1/LSIL HPV Persistent of the Cervix: Actual Progression or CIN3 Coexistence
por: Bruno, Maria Teresa, et al.
Publicado: (2021)

Conservative management of CIN2 p16 positive lesions in women with multiple HPV infection
por: Bruno, Maria Teresa, et al.
Publicado: (2020)

The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions
por: Dovnik, Andraž, et al.
Publicado: (2023)

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
por: Ibrahim Khalil, Ahmadaye, et al.
Publicado: (2023)

HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test
por: Halfon, Philippe, et al.
Publicado: (2013)

Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays
por: Halfon, Philippe, et al.
Publicado: (2013)

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
por: Kim, Tae Jin, et al.
Publicado: (2014)

The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
por: Ejegod, Ditte, et al.
Publicado: (2016)

Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021)

Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study
por: Valasoulis, George, et al.
Publicado: (2022)

HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant
por: van der Weele, Pascal, et al.
Publicado: (2019)

Improving the Quality of Healthcare Provision Regarding HPV Immunization for Women with CIN2+ Lesions: The Experience of the Veneto Region in Italy
por: De Polo, Anna, et al.
Publicado: (2023)

HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies
por: Giorgi Rossi, Paolo, et al.
Publicado: (2012)

HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway
por: Budal, Elisabeth B, et al.
Publicado: (2014)

Clinical and economic benefit of HPV-load testing in follow-up and management of women postcone biopsy for CIN2–3
por: Almog, B, et al.
Publicado: (2003)

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
por: Tewari, Krishnansu S.
Publicado: (2019)

Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions
por: Li, Yuejie, et al.
Publicado: (2019)

CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology
por: Pesic, Aleksandra, et al.
Publicado: (2019)

HPV58 E7 Protein Expression Profile in Cervical Cancer and CIN with Immunohistochemistry
por: Zheng, Qiaoli, et al.
Publicado: (2021)

CIN III lesions and regression: retrospective analysis of 635 cases
por: Motamedi, Melodi, et al.
Publicado: (2015)

The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan
por: Mikami, Mikio, et al.
Publicado: (2018)

The wages of CIN
por: Yuen, Karen W., et al.
Publicado: (2008)

The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections
por: Mattoscio, Domenico, et al.
Publicado: (2015)

CIN grades possessing different HPV RNA location patterns and RNAscope is helpful tool for distinguishing squamous intraepithelial lesions in difficult cervical cases
por: Chen, Ruichao, et al.
Publicado: (2023)

HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study
por: Naucler, P, et al.
Publicado: (2007)

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study
por: Munk, Ane Cecilie, et al.
Publicado: (2012)

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test
por: Polman, Nicole J, et al.
Publicado: (2017)

Underdiagnosis of cervical intraepithelial neoplasia (CIN) 2 or Worse Lesion in Women with a Previous Colposcopy-Guided Biopsy Showing CIN 1
por: Souza, Carlos André Scheler de, et al.
Publicado: (2017)

Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing
por: Kocken, M, et al.
Publicado: (2012)

Post-hysterectomy vaginal cuff cancer secondary to HPV infection and CIN: A case report
por: Liu, Xiaoxia, et al.
Publicado: (2013)

Correlation between Vaginal Microecological Status and Prognosis of CIN Patients with High-Risk HPV Infection
por: Zhang, Huizhen, et al.
Publicado: (2022)

HPV Opportunistic Vaccination: A Literature Review and a Single-Center Experience in Northern Italy through the COVID-19 Pandemic
por: Cantatore, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g32i9fp9jlpfm11d15iis9ku8i